Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotyping Clear all
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Genotype-Phenotype Urothelial Cancer Registry

NCT00902590
View directory record Official record
Conditions
Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
Interventions
saliva sample and questionaire, saliva sample, questionaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,519 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

TD-6450 MAD Study in HCV Infected Subjects

NCT02116543
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 20, 2026, 1:38 PM EDT
Active, not recruiting Not applicable Interventional

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

NCT02450708
View directory record Official record
Conditions
Leukemia
Interventions
KIR genotyping, HLA genotyping
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
10
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

NCT01247194
View directory record Official record
Conditions
Chronic Genotype 1 Hepatitis C Virus Infection
Interventions
PPI-461, Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 20, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia

NCT04980638
View directory record Official record
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Interventions
ER004
Biological
Lead sponsor
EspeRare Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 20, 2026, 1:38 PM EDT
Terminated No phase listed Observational

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

NCT00247689
View directory record Official record
Conditions
Substance Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational

Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

NCT01429155
View directory record Official record
Conditions
Hepatitis C
Interventions
Interleukin 28B genotype
Genetic
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer

NCT00433550
View directory record Official record
Conditions
Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Interventions
capecitabine, irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
115
States / cities
Hartford, Connecticut • Boise, Idaho • Cedar Rapids, Iowa + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 20, 2026, 1:38 PM EDT
Active, not recruiting No phase listed Observational

INHERIT EGFR - Studying Germline EGFR Mutations

NCT01754025
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

NCT01705925
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

Pharmacogenetic-guided Choice of Post-surgery Analgesics

NCT05548660
View directory record Official record
Conditions
Acute Pain, Post Operative Pain
Interventions
Pharmacogenetic testing, Pharmacist note with genotype-guided analgesic recommendations, Pharmacist detailed note with genotype-guided recommendations per CPIC guidelines
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270
View directory record Official record
Conditions
Hepatitis C
Interventions
BI201335, PegIFN/RBV, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

NCT00708773
View directory record Official record
Conditions
Advanced Cancer
Interventions
Irinotecan
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 20, 2026, 1:38 PM EDT
Recruiting No phase listed Observational

Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis

NCT06354010
View directory record Official record
Conditions
Sensorineural Hearing Loss, Bilateral
Interventions
Genotyping, Audiological assessments
Genetic · Other
Lead sponsor
Sensorion
Industry
Eligibility
30 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational

Characteristics of Nondystrophic Myotonias

NCT00244413
View directory record Official record
Conditions
Nondystrophic Myotonias, Myotonia Congenita, Myotonic Disorders
Interventions
Not listed
Lead sponsor
Richard Barohn, MD
Other
Eligibility
6 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Kansas City, Kansas • Boston, Massachusetts • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6

NCT02480166
View directory record Official record
Conditions
PT-NANBH
Interventions
8 weeks SOF/LED, 12 weeks SOF/LED
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Palo Alto, California • San Jose, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 20, 2026, 1:38 PM EDT
Completed No phase listed Observational

Genetics of Fatty Liver Disease in Children

NCT01966627
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
ogtt, genotyping, abdominal and liver magnetic resonance imaging, stool sample, liver biopsy
Other
Lead sponsor
Yale University
Other
Eligibility
7 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils

NCT02337231
View directory record Official record
Conditions
Genetic Differences of Lipid Metabolism/Healthy Subjects
Interventions
soybean oil and borage oil
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

NCT04996797
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo
Drug · Device · Other
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Mobile, Alabama • Phoenix, Arizona • Sun City, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Determinants of Response to Beta Blockade

NCT00837902
View directory record Official record
Conditions
Healthy
Interventions
Atenolol (β-blocker)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 20, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery

NCT03943927
View directory record Official record
Conditions
Post-operative Atrial Fibrillation
Interventions
Guided Metoprolol Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 20, 2026, 1:38 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

NCT06647459
View directory record Official record
Conditions
Ventricular Tachycardia, Atrial Fibrillation
Interventions
EP Study
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 20, 2026, 1:38 PM EDT